Premium
EFFECT OF TOPICAL PAROMOMYCIN ON CELL‐MEDIATED IMMUNITY DURING CUTANEOUS LEISHMANIASIS
Author(s) -
FRANKENBURG SHOSHANA,
GROSS ANAT,
JONAS FLORY,
KLAUS SIDNEY
Publication year - 1993
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1993.tb00975.x
Subject(s) - paromomycin , medicine , leishmaniasis , immunity , cell mediated immunity , cutaneous leishmaniasis , immunology , protozoal disease , cellular immunity , virology , dermatology , antibiotics , immune system , malaria , microbiology and biotechnology , aminoglycoside , biology
Background. The aim of this study was to evaluate the effect of topical paromomycin treatment on the development of immunity during cutaneous leishmaniasis. Methods. Three parameters of immunity were measured in the course of the disease: leishmanicidal effector activity, lymphocyte proliferation (cell‐mediated immunity), and antibody levels (humoral immunity). Peripheral blood specimens of 55 treated and 36 untreated patients were tested. Results. The main results of this study showed that there was a significant delay in the development of leishmanicidal effector activity and to a lesser extent also a delay in the development of antigen‐specific proliferative response in the treated compared with the untreated group. No difference was observed between the groups regarding the values achieved in the various tests. Conclusions. These results suggest that topical paromomycin treatment delays the development of cell‐mediated immunity but does not affect the levels of immunity that are eventually achieved.